drugset
drugset / Trial / NCT02549651

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

NCT02549651 ↗

Phase 1 Completed 32 enrolled MedImmune LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.

Timeline

Start
2016-07-13
Primary completion
2019-02-04
Completion
2019-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Danvatirsen Antisense oligonucleotide — Intravenous
Subject Durvalumab Monoclonal antibody — Intravenous
Subject Tremelimumab Monoclonal antibody — Intravenous

Indications

diffuse large B-cell lymphoma